- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06062420
Estudio de plataforma de fase 2 de nuevas combinaciones de inmunoterapia como tratamiento de primera línea en participantes con carcinoma de células escamosas de cabeza y cuello metastásico / recurrente positivo para PD-L1
Un estudio de plataforma de fase 2, aleatorizado, abierto, que utiliza un protocolo maestro para evaluar nuevas combinaciones de inmunoterapia como tratamiento de primera línea en participantes con carcinoma de células escamosas de cabeza y cuello positivo para PD-L1 recurrente/metastásico
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Aachen, Alemania, 52074
- GSK Investigational Site
-
Berlin, Alemania, 12203
- GSK Investigational Site
-
Giessen, Alemania, 35392
- GSK Investigational Site
-
Hamburg, Alemania, 20246
- GSK Investigational Site
-
Regensburg, Alemania, 93053
- GSK Investigational Site
-
Ulm, Alemania, 89075
- GSK Investigational Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Alemania, 60488
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Essen, North Rhine-Westphalia, Alemania, 45122
- GSK Investigational Site
-
-
-
-
-
Buenos Aires, Argentina, C1426ABP
- GSK Investigational Site
-
Capital Federal, Argentina, C1181ACH
- GSK Investigational Site
-
Ciudad Autonoma de Bueno, Argentina, C1056ABI
- GSK Investigational Site
-
Córdoba, Argentina, 5000
- GSK Investigational Site
-
Florida, Argentina, B1602DQD
- GSK Investigational Site
-
Mendoza, Argentina, M5500AYB
- GSK Investigational Site
-
San Juan, Argentina, 5400
- GSK Investigational Site
-
Santa Fe, Argentina, 3000
- GSK Investigational Site
-
-
-
-
-
Santo André, Brasil, 09060-650
- GSK Investigational Site
-
São Paulo, Brasil, 01246-000
- GSK Investigational Site
-
São Paulo, Brasil, 01221-020
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 5G2
- GSK Investigational Site
-
Edmonton, Alberta, Canadá, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
Toronto, Ontario, Canadá, M4N 3M5
- GSK Investigational Site
-
Toronto, Ontario, Canadá, M5G 2M9
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canadá, H3T 1E2
- GSK Investigational Site
-
-
-
-
-
Daegu, Corea del Sur, 42601
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do, Corea del Sur, 13620
- GSK Investigational Site
-
Seoul, Corea del Sur, 138-736
- GSK Investigational Site
-
Seoul, Corea del Sur, 03722
- GSK Investigational Site
-
Suwon Kyunggi-do, Corea del Sur, 443-721
- GSK Investigational Site
-
-
-
-
-
Herlev, Dinamarca
- GSK Investigational Site
-
-
-
-
-
Barcelona, España, 08035
- GSK Investigational Site
-
Barcelona, España, 08907
- GSK Investigational Site
-
Barcelona, España, 08023
- GSK Investigational Site
-
Jaén, España, 23007
- GSK Investigational Site
-
Madrid, España, 28041
- GSK Investigational Site
-
Madrid, España, 28040
- GSK Investigational Site
-
Madrid, España, 28034
- GSK Investigational Site
-
Madrid, España, 28010
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, España, 28223
- GSK Investigational Site
-
Salamanca, España, 37007
- GSK Investigational Site
-
Santander, España, 39008
- GSK Investigational Site
-
Valencia, España, 46009
- GSK Investigational Site
-
Zaragoza, España, 50009
- GSK Investigational Site
-
-
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06511
- GSK Investigational Site
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- GSK Investigational Site
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110-1010
- GSK Investigational Site
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- GSK Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- GSK Investigational Site
-
-
-
-
-
Turku, Finlandia, 20520
- GSK Investigational Site
-
-
-
-
-
Bordeaux, Francia, 33075
- GSK Investigational Site
-
Caen, Francia, 14075
- GSK Investigational Site
-
Marseille, Francia, 13005
- GSK Investigational Site
-
Paris, Francia, 75005
- GSK Investigational Site
-
Rouen, Francia, 76038
- GSK Investigational Site
-
Villejuif, Francia, 94805
- GSK Investigational Site
-
-
-
-
-
Haidari - Athens, Grecia, 12462
- GSK Investigational Site
-
Marousi, Grecia
- GSK Investigational Site
-
-
Central Macedonia
-
Panórama, Central Macedonia, Grecia, 552 36
- GSK Investigational Site
-
-
-
-
-
Győr, Hungría, 9024
- GSK Investigational Site
-
Kecskemét, Hungría, 6000
- GSK Investigational Site
-
Pécs, Hungría, 7624
- GSK Investigational Site
-
-
-
-
-
Bari, Italia, 70124
- GSK Investigational Site
-
Bologna, Italia, 40139
- GSK Investigational Site
-
Florence, Italia, 50134
- GSK Investigational Site
-
Genova, Italia, 16132
- GSK Investigational Site
-
Milan, Italia, 20133
- GSK Investigational Site
-
Naples, Italia, 80131
- GSK Investigational Site
-
Novara, Italia, 28100
- GSK Investigational Site
-
Padova, Italia, 35128
- GSK Investigational Site
-
Roma, Italia, 00168
- GSK Investigational Site
-
Roma, Italia, 00144
- GSK Investigational Site
-
-
MI
-
Rozzano, MI, Italia, 20089
- GSK Investigational Site
-
-
-
-
-
Aichi, Japón, 464-8681
- GSK Investigational Site
-
Chiba, Japón, 277-8577
- GSK Investigational Site
-
Hyōgo, Japón, 650-0017
- GSK Investigational Site
-
Osaka, Japón, 541-8567
- GSK Investigational Site
-
Saitama, Japón, 350-1298
- GSK Investigational Site
-
Shizuoka, Japón, 411-8777
- GSK Investigational Site
-
Tokyo, Japón, 104-0045
- GSK Investigational Site
-
-
-
-
-
Oslo, Noruega, 0379
- GSK Investigational Site
-
-
-
-
-
Bielsko-Biala, Polonia, 43-300
- GSK Investigational Site
-
Katowice, Polonia, 40-514
- GSK Investigational Site
-
Krakow, Polonia, 31-826
- GSK Investigational Site
-
Przemyśl, Polonia, 37-700
- GSK Investigational Site
-
Siedlce, Polonia, 08-110
- GSK Investigational Site
-
Warsaw, Polonia, 04-141
- GSK Investigational Site
-
-
-
-
-
Almada, Portugal, 2801-951
- GSK Investigational Site
-
Lisbon, Portugal, 1649-035
- GSK Investigational Site
-
Porto, Portugal, 4099-001
- GSK Investigational Site
-
Porto, Portugal, 4200-072
- GSK Investigational Site
-
-
-
-
-
Brasov, Rumania, 500283
- GSK Investigational Site
-
Bucharest, Rumania, 020142
- GSK Investigational Site
-
Bucharest, Rumania, 022328
- GSK Investigational Site
-
Bucharest, Rumania, 030171
- GSK Investigational Site
-
Bucharest, Rumania, 30463
- GSK Investigational Site
-
Craiova, Rumania, 200542
- GSK Investigational Site
-
Floreşti, Rumania, 407280
- GSK Investigational Site
-
Iași, Rumania, 700483
- GSK Investigational Site
-
Oradea, Rumania, 410469
- GSK Investigational Site
-
Piteşti, Rumania, 110283
- GSK Investigational Site
-
Suceava, Rumania, 720214
- GSK Investigational Site
-
-
-
-
-
Changhua, Taiwán, 500
- GSK Investigational Site
-
Tainan, Taiwán, 704
- GSK Investigational Site
-
Taipei, Taiwán, 11217
- GSK Investigational Site
-
Taipei, Taiwán, 10002
- GSK Investigational Site
-
-
-
-
-
Ankara, Turquía (Türkiye), 06100
- GSK Investigational Site
-
Istanbul, Turquía (Türkiye), 34662
- GSK Investigational Site
-
Izmir, Turquía (Türkiye), 35040
- GSK Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Have histologically or cytologically-confirmed HNSCC that is R/M and is considered incurable by local therapies. A) Subjects must not have had prior systemic therapy administered in the R/M setting. Chemoradiation therapy which was completed more than 4 months prior to signing consent if given as part of multimodal treatment for locally advanced disease is allowed B) The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx C) Subjects may not have a primary tumor site of nasopharynx (any histology)
- Has measurable (target) disease based on RECIST 1.1 as determined by the investigator.
- Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Provides a tumor tissue sample obtained at the time of or after the initial diagnosis of R/M HNSCC. A fresh tumor tissue sample obtained within 90 days of screening is highly preferred, If fresh biopsy is not possible, an archival tumor specimen is acceptable unless it was obtained prior to administration of chemoradiation for the treatment of a participant's tumor. Needle or excisional biopsies or resected tissue is required. Cytological specimens such as fine needle aspirates, bone marrow samples, or cell blocks are not acceptable. Bone specimen is not acceptable.
- Has tumor Programmed death ligand 1 (PD-L1) expression
- If the primary tumor site is oropharyngeal carcinoma, the participant must have Human papillomavirus (HPV) results
Exclusion Criteria:
- Has received prior therapy with any immune checkpoint inhibitors, including antibodies or drugs targeting Programmed death protein 1 (PD-1), PD-L1, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine based inhibitory motif domains (TIGIT), Cluster of differentiation (CD) 96, or other immune checkpoint pathways.
- Participants with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, esophageal, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period.
- Have active tumor bleeding or a high risk of bleeding (examples include but are not limited to radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrates >90 degree abutment or encasement of a major vessel [carotid, jugular, bronchial artery] and/or exhibits other high-risk features such as arteriovenous fistula).
- Has PD within 4 months of completion of curatively intended treatment for locoregionally advanced HNSCC
- Participants with any carcinomatous meningitis or leptomeningeal spread and those with uncontrolled or symptomatic Central Nervous System (CNS) metastases
- Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years. (Stable, medically managed autoimmune endocrinopathies are acceptable if participant otherwise meets entry criteria.)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Monoterapia con dostarlimab
|
Dostarlimab will be administered. |
|
Experimental: Subestudio 1: Dostarlimab y Belrestotug
|
Dostarlimab will be administered. Belrestotug will be administered. |
|
Experimental: Subestudio 2: Dostarlimab y nelistotug
|
Dostarlimab will be administered. Nelistotug will be administered. |
|
Experimental: Subestudio 3: Dosarlimab y Belrestotug y nelistotug
|
Dostarlimab will be administered. Belrestotug will be administered. Nelistotug will be administered. |
|
Experimental: Subestudio 4: Dostarlimab y remzistotug
|
Dostarlimab will be administered. Remzistotug will be administered. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Confirmed Objective Response Rate (ORR) compared between Sub studies and Dostarlimab monotherapy
Periodo de tiempo: Up to approximately 24 months
|
Confirmed ORR is defined as the percentage of participants achieving confirmed Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator assessment. |
Up to approximately 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Número de participantes con TEAE que llevaron a modificaciones de dosis o interrupción de la intervención del estudio
Periodo de tiempo: Hasta aproximadamente 24 meses
|
Hasta aproximadamente 24 meses
|
|
Número de participantes con hallazgos clínicamente significativos en signos vitales, electrocardiograma (ECG) y parámetros de pruebas de laboratorio
Periodo de tiempo: Hasta aproximadamente 24 meses
|
Hasta aproximadamente 24 meses
|
|
Número de participantes con eventos adversos (EA) emergentes del tratamiento, eventos adversos graves (EAG) emergentes del tratamiento y eventos adversos de interés especial (AESI) emergentes del tratamiento
Periodo de tiempo: Hasta aproximadamente 24 meses
|
Hasta aproximadamente 24 meses
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: GSK Clinical Trials, GlaxoSmithKline
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 219885
- 2023-503428-24 (Identificador de registro: CTIS)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Marco de tiempo para compartir IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Criterios de acceso compartido de IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .